330 related articles for article (PubMed ID: 29617189)
1. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL; Fung C; Monahan PO; Ardeshir-Rouhani-Fard S; Abu Zaid MI; Williams AM; Stump TE; Sesso HD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard C; Huddart RA; Kim J; Kollmannsberger C; Sahasrabudhe DM; Cook R; Fossa SD; Einhorn LH; Travis LB;
J Clin Oncol; 2018 May; 36(15):1505-1512. PubMed ID: 29617189
[TBL] [Abstract][Full Text] [Related]
2. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
Fung C; Sesso HD; Williams AM; Kerns SL; Monahan P; Abu Zaid M; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Kollmannsberger CK; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Lipshultz SE; Einhorn LH; Fossa SD; Travis LB;
J Clin Oncol; 2017 Apr; 35(11):1211-1222. PubMed ID: 28240972
[TBL] [Abstract][Full Text] [Related]
3. Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.
ArdeshirRouhaniFard S; Dinh PC; Monahan PO; Fossa SD; Huddart R; Fung C; Song Y; Feldman DR; Hamilton RJ; Vaughn DJ; Martin NE; Kollmannsberger C; Einhorn L; Kroenke K; Travis LB
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1129-1138. PubMed ID: 33849970
[TBL] [Abstract][Full Text] [Related]
4. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.
Brydøy M; Oldenburg J; Klepp O; Bremnes RM; Wist EA; Wentzel-Larsen T; Hauge ER; Dahl O; Fosså SD
J Natl Cancer Inst; 2009 Dec; 101(24):1682-95. PubMed ID: 19940282
[TBL] [Abstract][Full Text] [Related]
5. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M; Dinh PC; Monahan PO; Fung C; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Althouse S; Ardeshir-Rouhani-Fard S; Sesso HD; Huddart R; Mushiroda T; Kubo M; Dolan ME; Einhorn LH; Fossa SD; Travis LB;
J Natl Compr Canc Netw; 2019 May; 17(5):459-468. PubMed ID: 31085753
[TBL] [Abstract][Full Text] [Related]
6. Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.
Hjelle LV; Bremnes RM; Gundersen POM; Sprauten M; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Oldenburg J; Haugnes HS
Urol Oncol; 2016 Nov; 34(11):487.e13-487.e20. PubMed ID: 27523611
[TBL] [Abstract][Full Text] [Related]
7. Sexual Function in a Nationwide Cohort of 2,260 Survivors of Testicular Cancer after 17 Years of Followup.
Bandak M; Lauritsen J; Johansen C; Kreiberg M; Skøtt JW; Agerbaek M; Holm NV; Daugaard G
J Urol; 2018 Oct; 200(4):794-800. PubMed ID: 29730199
[TBL] [Abstract][Full Text] [Related]
8. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.
Feldman DR; Ardeshir-Rouhani-Fard S; Monahan P; Sesso HD; Fung C; Williams AM; Hamilton RJ; Vaughn DJ; Beard CJ; Cook R; Zaid MA; Lipshultz SE; Einhorn LH; Oeffinger KC; Travis LB; Fossa SD;
Clin Genitourin Cancer; 2018 Aug; 16(4):e761-e769. PubMed ID: 29534941
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
10. Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.
Solheim O; Skalleberg J; Warncke T; Ørstavik K; Tropé C; Fosså SD
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):240-249. PubMed ID: 30289161
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced toxicity in patients with testicular germ cell tumors: The impact of physical fitness and regular exercise.
Amiri A; Chovanec M; Oliva V; Sedliak M; Mego M; Ukropec J; Ukropcová B
Andrology; 2021 Nov; 9(6):1879-1892. PubMed ID: 34245663
[TBL] [Abstract][Full Text] [Related]
12. Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.
Fosså SD; Haugnes HS; Dahl AA; Kiserud CE; Fosså A; Skalleberg J; Myklebust TÅ
Ann Oncol; 2023 Dec; 34(12):1165-1174. PubMed ID: 37739265
[TBL] [Abstract][Full Text] [Related]
13. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
14. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).
Fosså SD; de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Cook P; de Prijck L; Stenning S; Aaronson NK; Bottomley A; Collette L; ;
J Clin Oncol; 2003 Mar; 21(6):1107-18. PubMed ID: 12637478
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
Trendowski MR; Wheeler HE; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2020 Dec; 26(24):6550-6558. PubMed ID: 32998964
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; Nuver J; de Wit R; Gietema JA; ten Bokkel Huinink WW; Rodrigus PT; Schimmel EC; Aleman BM; van Leeuwen FE
J Clin Oncol; 2006 Jan; 24(3):467-75. PubMed ID: 16421423
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
